Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2024
Reporting Period: Immediate event notification regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing does not contain financial performance data. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Listing Status
The Company received a notification from Nasdaq indicating non-compliance with continued listing requirements due to two primary factors:
- Annual Meeting Delay: Failure to hold the 2023 Annual Meeting within twelve months of the May 28, 2023 fiscal year end (Nasdaq Listing Rule 5620(a)).
- Reporting Delays: Continued delay in filing Quarterly Reports on Form 10-Q for the periods ended August 27, 2023, November 29, 2023, and February 25, 2024 (Nasdaq Listing Rules 5810(c)(2)(G) and 5250(c)(1)).
Nasdaq previously initiated a delisting process on February 13, 2024. The Company appealed this determination and appeared before the Nasdaq Hearings Panel on April 16, 2024, requesting a stay of suspension or delisting. A decision from the Hearings Panel is pending.
Outlook, Management Commentary, and Risks
Management Actions:
- The Board has scheduled the 2023 Annual Meeting for August 15, 2024.
- The Company intends to request an extension of time from the Hearings Panel to hold the meeting and file the overdue reports.
- Management states it is working diligently to complete the required filings.
Risks and Contingencies:
- There is no assurance that the overdue reports will be filed before any stay granted by Nasdaq expires.
- There is no assurance that the Annual Meeting will occur before any extension expires.
- There is no assurance that the Hearings Panel will grant a further stay or that the Company will regain compliance, which could result in delisting.
Immediate Impact: The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market.
Investor Verification Checklist
- Verify the status of the Nasdaq Hearings Panel decision regarding the appeal of the Staff Delisting Determination.
- Monitor the filing status of the overdue Form 10-Q reports for Q1, Q2, and Q3 of fiscal 2023.
- Confirm the execution of the 2023 Annual Meeting scheduled for August 15, 2024.
- Review the Company's most recent Form 10-K for detailed risk factors related to regulatory compliance.